Gene useful for diagnosis and treatment of aplasia of corpus...

Details Gene useful for diagnosis and treatment of aplasia of corpus... Gene useful for diagnosis and treatment of aplasia of corpus...

2006-07-25

2006-07-25

Fredman, Jeffrey (Department: 1637)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S091200

Reexamination Certificate

active

07081338

ABSTRACT:
Aplasia of the corpus callosum or aspermatogenesis is diagnosed by investigating existence or expression of the BT-IgSF gene with use of a primer for PCR or probe for hybridization comprising a DNA coding for a novel cell adhesion molecule (BT-IgSF) defined in the following (A) or (B) or a partial sequence thereof:(A) a protein comprising the amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2;(B) a protein comprising an amino acid sequence of the amino acid numbers 1 to 409 of SEQ ID NO: 2 including substitution, deletion, insertion or addition of one or several amino acids and having a function as a cell adhesion molecule.

REFERENCES:
patent: EO 1 211 313 (2002-06-01), None
patent: 11-018622 (1999-01-01), None
patent: WO 98/45434 (1998-10-01), None
patent: WO 00/00604 (2000-01-01), None
patent: WO 01/54474 (2001-08-01), None
patent: WO 01/54708 (2001-08-01), None
patent: WO 01/55315 (2001-08-01), None
patent: WO 01/75067 (2001-10-01), None
patent: WO 01/750967 (2001-10-01), None
Roche Diagnostics GmbH, Expand Long Template PCR System, Jun. 2002.
Buck, et al. Design strategies and performance of custom DNA sequencing primers. Biotechniques. Sep. 1999;27(3):528-36.
Genuardi, et al. A new case of interstitial deletion of chromosome 3q, del(3q)(q13.12q21.3), with agenesis of the corpus callosum. Clin Dysmorphol. Oct. 1994;3(4):292-6.
Ginzinger, DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp Hematol. Jun. 2002;30(6):503-12.
Ogilvie, et al. Deletion of chromosome 3q proximal region gives rise to a variable phenotype. Clin Genet. Mar. 1998;53(3):220-2.
Kuromitsu, et al. A unique downregulation of h2-calponin gene expression in Down syndrome: a possible attenuation mechanism for fetal survival by methylation at the CpG island in the trisomic chromosome 21.
Cyr, et al. “Identification and Developmental Regulation of Cadherin Messenger Ribonucleic Acids in the Rat Testis,”Endocrinology, vol. 131, No. 1, pp. 139-145, 1992.
Genuardi, et al. “A New Case of Interstitial Deletion of Chromosome 3q, del(3q)(q13.12q21.3) with Agenesis of the Corpus Callosum,”Clinical Dysmorphology, vol. 3, pp. 292-296, 1994.
Kamiguchi, et al. “Adhesion Molecules and Inherited Diseases of the Human Nervous System,”Annual Review of Neuroscience, vol. 21, pp. 97-125, 1998.
Ogilvie, et al. “Deletion of Chromosome 3q Proximal Region Gives Rise to a Variable Phenotype,”Clinical Genetics, vol. 53, pp. 220-222, 1998.
XP-002234524, Jan. 10, 2002, Abstract (WO 0154474 A) (EBI Database Accession No. ABB10359).
XP-002234525, Nov. 7, 2001, Abstract (WO 0155315 A) (EBI Database Accession No. AAU18038).
XP-002234526, Oct. 8, 2001, Abstract (EBI Database Accession No. BI830026).
Fechner, et al. “Expression of Coxsackie Adenovirus Receptor and Alphav-integrin Does Not Correlate with Adenovector Targeting In Vivo Indicating Anatomical Vector Barriers,”Gene Therapy, vol. 6, No. 9, pp. 1520-1535, 1999.
Suzu, et al. Molecular Cloning of a Novel Immunoglobulin Superfamily Gene Preferentially Expressed by Brain and Testis,Biochemical and Biophysical research Communications, vol. 296, No. 5, pp. 1215-1221, 2002.
European Search Report, dated Mar. 13, 2003, corresponding to to a related European patent application.
Geneseq Assession No. ABA06581 dated Jan. 10, 2002.
Geneseq Assession No. AAS28826, dated Nov. 7, 2001.
Geneseq Assession No. ABA06752, dated Jan. 10, 2002.
Geneseq Assession No. AAS28873, dated Nov. 7, 2001.
Geneseq Assession No. ABB10530, dated Jan. 10, 2002.
Geneseq Assession No. AAU18085, dated Nov. 7, 2001.
Geneseq Assession No. AAU18038, dated Nov. 7, 2001.
Geneseq Assession No. ABB10359, dated Jan. 10, 2002.
Geneseq Assession No. ABG16751, dated Feb. 18, 2002.

Affiliated with

Also associated with

Rating

Gene useful for diagnosis and treatment of aplasia of corpus... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene useful for diagnosis and treatment of aplasia of corpus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene useful for diagnosis and treatment of aplasia of corpus... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3592372